Skip to main content
SpringerLink
Log in

Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The effect of a synthetic analogue of CCK (Thr4,Nle7CCK-9) on growth of SW-1990 human pancreatic cancer was examined in two experimental models. Nude mice bearing SW-1990 pancreatic cancer xenografts were injected with CCK (5, 15, or 25μg/kg) or vehicle twice daily for 20 days. Animals were then sacrificed and tumor volume, weight, protein, and deoxyribonucleic acid (DNA) content were evaluated. SW-1990 cells were grown in vitro and the effects of CCK, secretin, vasoactive intestinal peptide (VIP), and proglumide (a CCK-receptor antagonist) on cell number and DNA synthesis were determined. The highest dose of CCK, 25 μg/kg, significantly increased tumor weight, protein content, and DNA content P<0.005). In vitro, CCK caused significant increases in cell counts of up to 47% at six days and 66% at 12 days compared to control. Graded concentrations of CCK had a biphasic effect on DNA synthesis with significant increases of up to 65% P<0.005). CCK-induced cell proliferation was inhibited by proglumide. Secretin slightly increased cancer cell growth, although not as potently as CCK. VIP or secretin in combination with CCK did not show potentiation. These results indicate that growth of some human pancreatic cancers may be influenced by gastrointestinal peptides, of which CCK is the most potent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mainz DL, Black O, Webster PD: Hormonal control of pancreatic growth. J Clin Invest 52:2300–2304, 1974

    Google Scholar 

  2. Dembinski AB, Johnson LR: Stimulation of pancreatic growth by secretin, caerulein, and pentagastrin. Endocrinology 106:323–328, 1980

    PubMed  Google Scholar 

  3. Morisset J, Chamberland S, Gilbert L, Lord A, Larose L: Study of pancreatic DNA synthesisin vivo andin vitro following caerulein treatment in vivo. Biomed Res 3:151–158, 1982

    Google Scholar 

  4. Solomon TE, Petersen H, Elashoff T, Grossman MI: Interaction of caerulein and secretin on pancreatic size and composition in rat. Am J Physiol 235:E714-E719, 1978

    PubMed  Google Scholar 

  5. Solomon TE, Vanier M, Morisset J: Cell site and time course of DNA synthesis in pancreas after caerulein and secretin. Am J Physiol 245:G99-G105, 1983

    PubMed  Google Scholar 

  6. Townsend CM, Singh P, Thompson JC: Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 91:1002–1006, 1986

    PubMed  Google Scholar 

  7. McGregor DB, Jones RD, Karlin DA, Romsdahl MM: Trophic effects of gastrin on colorectal neoplasms in the rat. Ann Surg 195:219–223, 1983

    Google Scholar 

  8. Winsett OE, Townsend CM, Glass EJ, Thompson JC: Gastrin stimulates growth of colon cancer. Surgery 99:302–307, 1986

    PubMed  Google Scholar 

  9. Smith JP, Solomon TE: Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 95:1541–1548, 1988

    PubMed  Google Scholar 

  10. Longnecker DS, Lhoste EF, Roebuck BD: Enhancement of growth and conversion of phenotype in azaserine-induced acinar cell foci of rats fed FOY-305. Fed Proc 46:586, 1987 (abstract)

    Google Scholar 

  11. McGuiness EE, Morgan RCH, Levison DA, Hopwood D, Wormsley KG: Interaction of azaserine and raw soya flour on the rat pancreas. Scand J Gastroenterol 16:49–56, 1981

    PubMed  Google Scholar 

  12. Howatson AG, Carter DC: Pancreatic carcinogenesisenhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer 51:107–114, 1985

    PubMed  Google Scholar 

  13. Johnson FE, LaRegina MC, Martin SA, Bashiti HM: Cholecystokinin inhibits pancreatic and hepatic carcinogenesis. Cancer Detect Prev 6:389–402, 1983

    PubMed  Google Scholar 

  14. Andren-Sanberg A, Dawiskiba S, Ihse I: Studies of the effect of caerulein administration on experimental pancreatic carcinogenesis. Scand J Gastroenterol 19:122–178, 1984

    PubMed  Google Scholar 

  15. Townsend CM, Franklin RB, Watson LC, Glass EJ, Thompson JC: Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 32:228–229, 1981

    Google Scholar 

  16. Smith JP, Barrett B, Solomon TE: CCK stimulates growth of five human pancreatic cancer cell lines in serum-free medium. Gastroenterology 92:1646, 1987 (abstract)

    Google Scholar 

  17. Hudd C, LaRegina MC, Devine JE, Palmer DC, Herbold DR, Beinfeld MC, Gelder FB, Johnson FE: Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice. Am J Surg 157:386–394, 1989

    PubMed  Google Scholar 

  18. Maani R, Townsend CM, Gomez G, Thompson JC, Singh P: A potent CCK receptor antagonist (L364,718) inhibits growth of human pancreatic cancer in nude mice. Gastroenterology 94:A274, 1988 (abstract)

    Google Scholar 

  19. Singh P, Townsend CM, Upp J, Laridjani A, Thompson JC: Characterization of cholecystokinin receptors (CCK-R) in normal and cancerous human pancreas. Fed Proc 45(3):91, 1986 (abstract)

    Google Scholar 

  20. Estival A, Clemente F, Ribet A: Adenocarcinoma of the human exocrine pancreas: Presence of secretin and caerulein receptors. Biochem Biophys Res Commun 102:1336–1341, 1981

    PubMed  Google Scholar 

  21. Jensen RT, Zhou ZC, Murphy RB, Jones SW, Setnikar I, Rovati LA, Gardner JD: Structural features of various proglumide-related cholecystokinin receptor antagonists. Am J Physiol 251:G839-G846, 1986

    PubMed  Google Scholar 

  22. Rovati AL: The relationship between chemical structure of a new dicarboxylic amino acid derivative and antigastrin activity in the rat. Br J Pharmacol 34:677–682, 1968

    Google Scholar 

  23. Johnson LR, Guthrie PD: Proglumide inhibition of trophic action of pentagastrin. Am J Physiol 246:G62-G66, 1984

    PubMed  Google Scholar 

  24. Yamaguchi T, Tabata K, Johnson LR: Effect of proglumide on rat pancreatic growth. Am J Physiol 249:G294-G298, 1985

    PubMed  Google Scholar 

  25. Niederau C, Ferrell LD, Grendell JH: Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript and secretin. Gastroenterology 88:1192–1204, 1985

    PubMed  Google Scholar 

  26. Smith JP, Kramer S, Bagheri S. Effects of a high fat diet and L364,718 on growth of human pancreas cancer. Dig Dis Sci 35:726–732, 1990

    PubMed  Google Scholar 

  27. Douglas BR, Woutersen RA, Jansen GJMJ, DeJong AJL, Rovati LC, Lamers CBHW: Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 96:462–469, 1989

    PubMed  Google Scholar 

  28. Kyriazis AP, McCombs III WB, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R: Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res 43:4393–4401, 1983

    PubMed  Google Scholar 

  29. Osieka R, Houchens DP, Goldin A, Johnson RK: Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40:2640–2650, 1977

    PubMed  Google Scholar 

  30. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275, 1951

    PubMed  Google Scholar 

  31. Burton K: A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315–323, 1956

    PubMed  Google Scholar 

  32. Norell SE, Ahlbom A, Erwald R, Jacobson G, Lindberg-Navier I, Olin R, Tornberg B, Wiechel KL: Diet and pancreatic cancer: A case-control study. Am J Epidemiol 124:894–902, 1986

    PubMed  Google Scholar 

  33. Hopkins GJ, West CE: Possible roles of dietary fats in carcinogenesis. Life Sci 19:1103–1116, 1976

    PubMed  Google Scholar 

  34. Meyer J, Jones R: Canine pancreatic responses to intestinally perfused fat and products of fat digestion. Am J Physiol 226:1178–1187, 1974

    PubMed  Google Scholar 

  35. Liddle R, Goldfine I, Rosen M, Taplitz R, Williams J: Cholecystokinin bioactivity in human plasma: Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75:1144–1152, 1985

    PubMed  Google Scholar 

  36. Lhoste EF, Longnecker DS: Effects of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas. Cancer Res 47:3273–3277, 1987

    PubMed  Google Scholar 

  37. Pour PM, Runge RG, Birt D, Gingell R, Lawson T, Nagel D, Wallcave L, Salmasi SZ: Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to human disease. Cancer 47:1573–1587, 1981

    PubMed  Google Scholar 

  38. Solomon TE, Morisset J, Wood JG, Bussjaeger LJ: Additive interaction of pentagastrin and secretin on pancreatic growth in rats. Gastroenterology 92:429–435, 1987

    PubMed  Google Scholar 

  39. Upp JR, Olson D, Poston GJ, Alexander RW, Townsend CM Jr, Thompson JC: Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995, Am J Surg 155:29–42, 1988

    PubMed  Google Scholar 

  40. Johnson FE, Hudd C, LaRegina MC, Devine JE: Effect of chronically administered cholecystokinin on the nude mouse. J Surg Res 46:177–183, 1989

    PubMed  Google Scholar 

  41. Poston GJ, Yao CZ, Upp JR Jr, Alexander RW, Townsend CM Jr, Thompson JC: Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancerin vivo. Pancreas 3:439–443, 1988

    PubMed  Google Scholar 

  42. Estival A, Mounielou P, Trocheris V, Scemama JL, Clemente F, Hollande E, Rabit A: Presence of VIP receptors in a human pancreatic adenocarcinoma cell line. Modulation of the cAMP response during cell proliferation. Biochem Biophys Res Commun 111:958–963, 1983

    PubMed  Google Scholar 

  43. Howard JM, Knight M, Jensen RT, Gardner JD: Discovery of a cholecystokinin analogue with partial agonist activities. Am J Physiol 247:G261-G264, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Physiology, Kansas University Medical Center, Kansas City, Kansas

    Jill Palmer Smith MD, Travis E. Solomon MD, PhD, Saeed Bagheri MD & Scott Kramer BA

  2. Veterans Administration Medical Center, Kansas City, Missouri

    Jill Palmer Smith MD, Travis E. Solomon MD, PhD, Saeed Bagheri MD & Scott Kramer BA

  3. Department of Medicine, Veterans Administration Hospital, Lebanon, Pennsylvania

    Jill Palmer Smith MD, Travis E. Solomon MD, PhD, Saeed Bagheri MD & Scott Kramer BA

Authors
  1. Jill Palmer Smith MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Travis E. Solomon MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saeed Bagheri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott Kramer BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by Grant IN-109L from the American Cancer Society, grants DK35152 and CA50303-01 from the National Institutes of Health, and by the Research Services of the Veterans Administration.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, J.P., Solomon, T.E., Bagheri, S. et al. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Digest Dis Sci 35, 1377–1384 (1990). https://doi.org/10.1007/BF01536744

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01536744

Key words

Search

Navigation